genosmart DX Prostate Cancer ^SolidRNA-8

The therapy-focused hotspot panel for prostate cancers

Useful for

The DB-RNA-ProstateCancer-Solid8 Panel is a targeted resequencing assay for the biomarker analysis of 8 genes with known relevance to prostate tumours. Within these 8 genes 25 targets are specifically examined.

Speciment type requirements

50 ng (min. 5 ng/ul) purified DNA from FFPE or frozen tumour samples

Required information

DNA concentration and tumour ratio

Clinical interpretation

Targeted cancer therapies are defined as antibody or small molecule drugs that block the growth and spread of cancer by interfering with specific cell molecules involved in tumour growth and progression. Multiple targeted therapies have been approved for treatment of specific cancers. Molecular genetic profiling is often needed to identify targets amenable to targeted therapies and to minimize treatment costs and therapy-associated risks.

Cautions

This test cannot differentiate between somatic and germline alterations. Additional testing may be necessary to clarify the significance of results if there is a potential hereditary risk. DNA variants of uncertain significance may be identified. A negative (wild-type) result does not rule out the presence of a mutation or rearrangement (fusion) that may be present but below the limits of detection of this assay. Rare polymorphisms may be present that could lead to false-negative or false-positive results. Test results should be interpreted in the context of clinical findings, tumour sampling, and other laboratory data. If results obtained do not match other clinical or laboratory findings, please contact the laboratory for updated interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.